Inactive Instrument

CELLCEUTIX Share Price OTC Bulletin Board

Equities

CTIX

US15115V1017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for CELLCEUTIX
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 0.02 1.5 Sales 2023 - Capitalization 1.04Cr 87Cr
Net income 2022 -70L -58Cr Net income 2023 -30L -25Cr EV / Sales 2022 67,33,26,722 x
Net cash position 2022 25.19L 21Cr Net cash position 2023 8L 6.62Cr EV / Sales 2023 -
P/E ratio 2022
-2.22 x
P/E ratio 2023
-3.19 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 87.87%
More Fundamentals * Assessed data
Innovation Pharmaceuticals Inc. Announces Resignation of Board Members CI
Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Innovation Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt CI
Innovation Pharmaceuticals Inc. acquired an unknown minority stake in Squalus Medical. CI
Squalus Medical announced that it has received $4.999968 million in funding from Innovation Pharmaceuticals Inc., and other investors CI
Innovation Pharmaceuticals Inc. announced a financing transaction CI
More news
Managers TitleAgeSince
Chief Executive Officer 66 20/07/20
Chief Tech/Sci/R&D Officer 55 01/16/01
Members of the board TitleAgeSince
Chief Executive Officer 66 20/07/20
More insiders
Innovation Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company is primarily focused on business development for the advancement of Brilacidin in the treatment of infectious diseases and oral mucositis. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. Brilacidin is also developed as a treatment in more extensive forms of inflammatory bowel disease (IBD). It is engaged in developing an image guided surgical laser platform, through BT BeaMedical Technologies Ltd. It is also engaged in business development and licensing initiatives with specialty and global pharmaceutical companies.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW